EUVIMEDEUVIMED entdecken
Open Access

Ser423-phosphorylated MECP2 (MECP2-pS423) accumulates in human brain, cerebrospinal fluid and serum in sporadic Alzheimer’s disease

Qing-Rong Liu, Min Zhu, Kevin Perez, Qin Yao, Mark S Horowitz, Qinghua Chen, Giovanna Fantoni, Yang An, Susan M Resnick, Andrea Sedlock, Dragan Maric, Geidy E Serrano und 2 weitere

Acta Neuropathologica · 15.04.2026 · 151 (1)

DOI: 10.1007/s00401-026-03008-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 15.04.2026. Verfasst von Qing-Rong Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Investigation, National Institute On Aging, National Institutes of Health, 251 Bayview Blvd, Baltimore, MD, 21224, USA. qingro…. Hauptthemen laut MEDLINE: Alzheimer Disease, Methyl-CpG-Binding Protein 2, Brain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, NINDS NIH HHS, Josephine M. Egan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methyl-CpG-binding protein 2 (MECP2) is a nuclear protein that serves as a global epigenetic repressor. Activity-dependent Ser421-phosphorylation is permissive to translocation of mouse Mecp2 to the cytoplasm, thereby reducing the repressor functions and activating neurotrophins. Mecp2-pS421 levels increase in neuron soma of AD (APP/PS1) mouse model and ablating Mecp2 increases activity of glycogen synthase kinase 3 beta, implying a link between MECP2 phosphorylation and Tau pathology in Alzheimer's disease (AD). It is currently unknown whether phosphorylation at the corresponding site of human MECP2-pS423 plays a role in AD. We developed an MECP2-pS423-specific antibody, and a quantitative selective reaction monitoring (SRM) assay based on LC-MS/MS analysis, and we used immunohistochemistry and proteomics to study MECP2-pS423 in human brain, cerebrospinal fluid (CSF), and serum specimens. In postmortem cortex and hippocampus, MECP2-pS423 expression increased across the clinicopathological spectrum of AD and correlated with histological progression and cognitive deficits. At the cellular level, MECP2-pS423 and pTau colocalized in granulovacuolar degeneration (GVD) bodies and neuritic plaques. Phosphoprotein levels of MECP2-pS423 increased in CSF and serum samples from patients clinically diagnosed as having AD premortem. Moreover, we found that a primate-specific and N-terminus truncated MECP2-E3 isoform mRNA was increased in postmortem middle temporal gyrus (MTG) of patients with AD. The results suggest that MECP2-pS423 is a promising mechanism-based biomarker and potential therapeutic target because its accumulations correlate with pathological and cognitive deficit in brain, CSF, and serum of human sporadic AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMethyl-CpG-Binding Protein 2BrainHumansPhosphorylationMaleAged, 80 and overFemaleAnimalsAgedSerinetau ProteinsMiddle Aged

Stichwörter der Autor:innen

Alzheimer’s diseaseEpigeneticsGranulovacuolar degenerationMECP2PhosphorylationTau

Substanzen

Methyl-CpG-Binding Protein 2MECP2 protein, humanSerinetau Proteins

Autor:innen und Institutionen

  • Laboratory of Clinical Investigation, National Institute On Aging, National Institutes of Health, 251 Bayview Blvd, Baltimore, MD, 21224, USA. qingrong.liu@nih.gov.
  • Laboratory of Clinical Investigation, National Institute On Aging, National Institutes of Health, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
  • Laboratory of Behavioral Neuroscience, National Institute On Aging, National Institutes of Health, 251 Bayview Blvd, Baltimore, MD, 21224, USA.
  • Flow and Imaging Cytometry Core Facility, National Institute of Neurological Disorders and Stroke, NIH, 9000 Rockville Pike, Bethesda, MD, 20892, USA.
  • Laboratory of Neuropathology, Banner Sun Health Research Institute, 10515 W Santa Fe Dr, Sun City, AZ, 85351, USA.
  • Laboratory of Clinical Investigation, National Institute On Aging, National Institutes of Health, 251 Bayview Blvd, Baltimore, MD, 21224, USA. chris.ramsden@nih.gov.

Förderung

  • Intramural NIH HHS
  • NINDS NIH HHS
  • Josephine M. Egan
  • NIA NIH HHS

Zitieren

APA

Liu, Q. R., Zhu, M., Perez, K., Yao, Q., Horowitz, M. S., Chen, Q., Fantoni, G., An, Y., Resnick, S. M., Sedlock, A., Maric, D., Serrano, G. E., Egan, J. M., & Ramsden, C. E. (2026). Ser423-phosphorylated MECP2 (MECP2-pS423) accumulates in human brain, cerebrospinal fluid and serum in sporadic Alzheimer’s disease. Acta Neuropathologica, 151(1). https://doi.org/10.1007/s00401-026-03008-3

Vancouver

Liu QR, Zhu M, Perez K, Yao Q, Horowitz MS, Chen Q, et al. Ser423-phosphorylated MECP2 (MECP2-pS423) accumulates in human brain, cerebrospinal fluid and serum in sporadic Alzheimer’s disease. Acta Neuropathologica. 2026;151(1). doi:10.1007/s00401-026-03008-3

BibTeX
@article{Liu2026,
  author = {Liu, Qing-Rong and Zhu, Min and Perez, Kevin and Yao, Qin and Horowitz, Mark S and Chen, Qinghua and Fantoni, Giovanna and An, Yang and Resnick, Susan M and Sedlock, Andrea and Maric, Dragan and Serrano, Geidy E and Egan, Josephine M and Ramsden, Christopher E},
  title = {Ser423-phosphorylated MECP2 (MECP2-pS423) accumulates in human brain, cerebrospinal fluid and serum in sporadic Alzheimer’s disease},
  journal = {Acta Neuropathologica},
  year = {2026},
  volume = {151},
  number = {1},
  doi = {10.1007/s00401-026-03008-3}
}
Kostenlos starten →